Zaklina Kovacevic

List of Publications by Year
in descending order

86 papers	4,791 citations	76326 40 h-index	98798 67 g-index
91 all docs	91 docs citations	91 times ranked	5868 citing authors

#	Article	IF	Citations
1	Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation ofÂtheÂmetastasis suppressor NDRG1. Journal of Biological Chemistry, 2022, 298, 101608.	3.4	20
2	Breaking the cycle: Targeting of NDRG1 to inhibit biâ€directional oncogenic crossâ€talk between pancreatic cancer and stroma. FASEB Journal, 2021, 35, e21347.	0.5	23
3	The metastasis suppressor NDRG1 directly regulates androgen receptor signaling in prostate cancer. Journal of Biological Chemistry, 2021, 297, 101414.	3.4	18
4	Pharmacological targeting and the diverse functions of the metastasis suppressor, NDRG1, in cancer. Free Radical Biology and Medicine, 2020, 157, 154-175.	2.9	47
5	Unique targeting of androgenâ€dependent and â€independent AR signaling in prostate cancer to overcome androgen resistance. FASEB Journal, 2020, 34, 11511-11528.	0.5	25
6	Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding. Journal of Biological Chemistry, 2020, 295, 481-503.	3.4	18
7	Overcoming tamoxifen resistance in oestrogen receptorâ€positive breast cancer using the novel thiosemicarbazone antiâ€cancer agent, <scp>DpC</scp>. British Journal of Pharmacology, 2020, 177, 2365-2380.	5.4	21
8	Abstract P2-04-02: Progesterone receptor membrane component 1 - A novel key regulator in lipid homeostasis drives oncogenic signaling resulting in breast cancer progression. , 2020, , .		0
9	Synthesis, Characterization, and in Vitro Anticancer Activity of Copper and Zinc Bis(Thiosemicarbazone) Complexes. Inorganic Chemistry, 2019, 58, 13709-13723.	4.0	78
10	The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6. Journal of Biological Chemistry, 2019, 294, 4045-4064.	3.4	33
11	Exploiting Cancer Metal Metabolism using Anti-Cancer Metal- Binding Agents. Current Medicinal Chemistry, 2019, 26, 302-322.	2.4	19
12	Tumor-induced neoangiogenesis and receptor tyrosine kinases â€“ Mechanisms and strategies for acquired resistance. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 1217-1225.	2.4	9
13	Two mechanisms involving the autophagic and proteasomal pathways process the metastasis suppressor protein, N-myc downstream regulated gene 1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1361-1378.	3.8	12
14	E6AP Promotes a Metastatic Phenotype in Prostate Cancer. IScience, 2019, 22, 1-15.	4.1	11
15	The metastasis suppressor, NDRG1, attenuates oncogenic TGF-Î² and NF-ÎºB signaling to enhance membrane E-cadherin expression in pancreatic cancer cells. Carcinogenesis, 2019, 40, 805-818.	2.8	45
16	Targeting Oncogenic Nuclear Factor Kappa B Signaling with Redox-Active Agents for Cancer Treatment. Antioxidants and Redox Signaling, 2019, 30, 1096-1123.	5.4	21
17	Ironing out the role of the cyclin-dependent kinase inhibitor, p21 in cancer: Novel iron chelating agents to target p21 expression and activity. Free Radical Biology and Medicine, 2019, 133, 276-294.	2.9	27
18	Abstract A16: A novel therapeutic approach to inhibit the bidirectional oncogenic crosstalk between pancreatic cancer cells and the surrounding stroma. , 2019, , .		0

#	Article	IF	Citations
19	Identification of differential phosphorylation and sub-cellular localization of the metastasis suppressor, NDRG1. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2644-2663.	3.8	36
20	Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21 CIP1/WAF1 , by the chelator, Dp44mT. Biochimica Et Biophysica Acta - General Subjects, 2018, 1862, 761-774.	2.4	10
21	Abstract A165: Novel thiosemicarbazone, Dp44mT, promotes NDRG1 to downregulate oncogenic signaling pathways in cancer. , 2018, , .		0
22	Abstract B212: N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. , 2018, , .		0
23	Regulation and control of nitric oxide (NO) in macrophages: Protecting the â€œprofessional killer cellâ€• from its own cytotoxic arsenal via MRP1 and GSTP1. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 995-999.	2.4	32
24	Novel Thiosemicarbazones Inhibit Lysine-Rich Carcinoembryonic Antigenâ€“Related Cell Adhesion Molecule 1 (CEACAM1) Coisolated (LYRIC) and the LYRIC-Induced Epithelial-Mesenchymal Transition via Upregulation of N-Myc Downstream-Regulated Gene 1 (NDRG1). Molecular Pharmacology, 2017, 91, 499-517.	2.3	22
25	Interplay of the iron-regulated metastasis suppressor NDRG1 with epidermal growth factor receptor (EGFR) and oncogenic signaling. Journal of Biological Chemistry, 2017, 292, 12772-12782.	3.4	48
26	Metals and metastasis: Exploiting the role of metals in cancer metastasis to develop novel anti-metastatic agents. Pharmacological Research, 2017, 115, 275-287.	7.1	56
27	PGRMC1 regulation by phosphorylation: potential new insights in controlling biological activity. Oncotarget, 2016, 7, 50822-50827.	1.8	35
28	Targeting autophagy in antitumor agent design: furthering the â€˜lysosomal loveâ€™ strategy. Future Medicinal Chemistry, 2016, 8, 727-729.	2.3	0
29	Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2Î±, IRE1Î±, ATF6 and calmodulin kinase. Biochemical Pharmacology, 2016, 109, 27-47.	4.4	36
30	Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling. Molecular Pharmacology, 2016, 89, 521-540.	2.3	45
31	Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia. Clinical Science, 2016, 130, 853-870.	4.3	45
32	A Nitric Oxide Storage and Transport System That Protects Activated Macrophages from Endogenous Nitric Oxide Cytotoxicity. Journal of Biological Chemistry, 2016, 291, 27042-27061.	3.4	32
33	The emerging role of progesterone receptor membrane component 1 (PGRMC1) in cancer biology. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 339-349.	7.4	63
34	The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms. Journal of Hematology and Oncology, 2016, 9, 98.	17.0	94
35	Lysosomal membrane stability plays a major role in the cytotoxic activity of the anti-proliferative agent, di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT). Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 1665-1681.	4.1	34
36	Copper and conquer: copper complexes of di-2-pyridylketone thiosemicarbazones as novel anti-cancer therapeutics. Metallomics, 2016, 8, 874-886.	2.4	105

#	Article	IF	Citations
37	The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways. Journal of Biological Chemistry, 2016, 291, 1029-1052.	3.4	65
38	Novel Mechanism of Cytotoxicity for the Selective Selenosemicarbazone, 2-Acetylpyridine 4,4-Dimethyl-3-selenosemicarbazone (Ap44mSe): Lysosomal Membrane Permeabilization. Journal of Medicinal Chemistry, 2016, 59, 294-312.	6.4	39
39	Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 770-784.	4.1	148
40	Redox cycling metals: Pedaling their roles in metabolism and their use in the development of novel therapeutics. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 727-748.	4.1	111
41	Copper that cancer with lysosomal love!. Aging, 2016, 8, 210-211.	3.1	10
42	Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget, 2015, 6, 18748-18779.	1.8	137
43	The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget, 2015, 6, 8851-8874.	1.8	64
44	Making a case for albumin â€“ a highly promising drug-delivery system. Future Medicinal Chemistry, 2015, 7, 553-556.	2.3	17
45	Novel Thiosemicarbazones Regulate the Signal Transducer and Activator of Transcription 3 (STAT3) Pathway: Inhibition of Constitutive and Interleukin 6â€“Induced Activation by Iron Depletion. Molecular Pharmacology, 2015, 87, 543-560.	2.3	37
46	The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the â€œTriad of Deathâ€•in cancer by Di-2-pyridylketone thiosemicarbazones. Pharmacological Research, 2015, 100, 255-260.	7.1	127
47	Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types. Oncotarget, 2015, 6, 29694-29711.	1.8	15
48	The metastasis suppressor, NDRG1, inhibits â€œstemnessâ€•of colorectal cancer via down-regulation of nuclear Î²-catenin and CD44. Oncotarget, 2015, 6, 33893-33911.	1.8	40
49	The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targets. Oncotarget, 2015, 6, 35522-35541.	1.8	43
50	Abstract A63: Role of the metastasis suppressor, NDRG1, in regulating the EGFR and ErbB family of receptors and its effects on key oncogenic signaling pathways in pancreatic cancer. , 2015, , .		0
51	The Metastasis Suppressor, N-myc Downstream-regulated Gene 1 (NDRG1), Inhibits Stress-induced Autophagy in Cancer Cells. Journal of Biological Chemistry, 2014, 289, 9692-9709.	3.4	83
52	Glutathione S-transferase and MRP1 form an integrated system involved in the storage and transport of dinitrosylâ€“dithiolato iron complexes in cells. Free Radical Biology and Medicine, 2014, 75, 14-29.	2.9	29
53	Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelialâ€“mesenchymal transition. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 166-181.	7.4	50
54	Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 1-19.	7.4	88

#	Article	IF	Citations
55	The metastasis suppressor, NDRG1, modulates Î²-Catenin phosphorylation and nuclear translocation by mechanisms involving FRAT1 and PAK4. Journal of Cell Science, 2014, 127, 3116-30.	2.0	93
56	Targeting the Metastasis Suppressor, NDRG1, Using Novel Iron Chelators: Regulation of Stress Fiber-Mediated Tumor Cell Migration via Modulation of the ROCK1/pMLC2 Signaling Pathway. Molecular Pharmacology, 2013, 83, 454-469.	2.3	90
57	The Iron-Regulated Metastasis Suppressor NDRG1 Targets NEDD4L, PTEN, and SMAD4 and Inhibits the PI3K and Ras Signaling Pathways. Antioxidants and Redox Signaling, 2013, 18, 874-887.	5.4	151
58	The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Molecular Pharmacology, 2013, 83, 179-190.	2.3	106
59	Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis, 2013, 34, 1943-1954.	2.8	117
60	The redox-active, anti-cancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism. Redox Report, 2013, 18, 48-50.	4.5	3
61	The role of NDRG1 in the pathology and potential treatment of human cancers. Journal of Clinical Pathology, 2013, 66, 911-917.	2.0	72
62	Dp44mT targets the AKT, TGF-Î² and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. British Journal of Cancer, 2013, 108, 409-419.	6.4	100
63	N-myc Downstream Regulated 1 (NDRG1) Is Regulated by Eukaryotic Initiation Factor 3a (eIF3a) during Cellular Stress Caused by Iron Depletion. PLoS ONE, 2013, 8, e57273.	2.5	59
64	Iron Chelation: Inhibition of Key Signaling Pathways in the Induction of the Epithelial Mesenchymal Transition in Pancreatic Cancer and Other Tumors. Critical Reviews in Oncogenesis, 2013, 18, 409-434.	0.4	15
65	Abstract A232: Novel thiosemicarbazones with potent antitumor and antimetastatic activity inhibit the signal transducer and activator of transcription (STAT) pathway.. , 2013, , .		0
66	Iron Chelators for the Treatment of Cancer. Current Medicinal Chemistry, 2012, 19, 2689-2702.	2.4	158
67	The Iron Chelators Dp44mT and DFO Inhibit TGF-Î²-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1). Journal of Biological Chemistry, 2012, 287, 17016-17028.	3.4	213
68	Synthesis and characterization of quinoline-based thiosemicarbazones and correlation of cellular iron-binding efficacy to anti-tumor efficacy. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5527-5531.	2.2	61
69	Targeting Iron in Cancer Cells: A New Strategy to Inhibit Metastatic Progression. , 2012, 01, .		2
70	Siderocalin/Lcn2/NGAL/24p3 Does Not Drive Apoptosis Through Gentisic Acid Mediated Iron Withdrawal in Hematopoietic Cell Lines. PLoS ONE, 2012, 7, e43696.	2.5	45
71	Targeting the Metastasis Suppressor NDRG1: A New Strategy for the Treatment of Pancreatic Cancer. FASEB Journal, 2012, 26, 761.28.	0.5	0
72	Chelators to the Rescue: Different Horses for Different Courses!. Chemical Research in Toxicology, 2011, 24, 279-282.	3.3	8

#	Article	IF	Citations
73	Research Spotlight: Iron chelation: deciphering novel molecular targets for cancer therapy. The tip of the iceberg of a web of iron-regulated molecules. Future Medicinal Chemistry, 2011, 3, 1983-1986.	2.3	5
74	The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer. Current Topics in Medicinal Chemistry, 2011, 11, 483-499.	2.1	69
75	Novel Thiosemicarbazone Iron Chelators Induce Up-Regulation and Phosphorylation of the Metastasis Suppressor N-myc Down-Stream Regulated Gene 1: A New Strategy for the Treatment of Pancreatic Cancer. Molecular Pharmacology, 2011, 80, 598-609.	2.3	154
76	The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis, 2011, 32, 732-740.	2.8	76
77	Abstract A67: Mechanisms involved in regulating the expression of the cyclin-dependent kinase (cdk) inhibitor, p21, by intracellular iron levels.. , 2011, , .		1
78	Investigating the anti-proliferative activity of styrylazanaphthalenes and azanaphthalenediones. Bioorganic and Medicinal Chemistry, 2010, 18, 2664-2671.	3.0	44
79	Investigating the Spectrum of Biological Activity of Ring-Substituted Salicylanilides and Carbamoylphenylcarbamates. Molecules, 2010, 15, 8122-8142.	3.8	40
80	Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity. Current Drug Delivery, 2010, 7, 194-207.	1.6	14
81	The TGF-Î², PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochemical Journal, 2009, 417, 411-421.	3.7	86
82	Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 5271-5294.	6.4	338
83	Abstract B172: The metastasis suppressor NDRG1 upâ€regulates p21 in a p53â€independent manner in cancer cells: A novel insight into its antitumor function. , 2009, , .		0
84	The iron-regulated metastasis suppressor, Ndrg-1: Identification of novel molecular targets. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 1981-1992.	4.1	70
85	Tuning Cell Cycle Regulation with an Iron Key. Cell Cycle, 2007, 6, 1982-1994.	2.6	206
86	The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis, 2006, 27, 2355-2366.	2.8	168